This review demonstrates the integration of multiomics to improve treatment outcomes in oncology, suggesting broader implementation in clinical practice.
Key Points
The aim is to explore how integrated multiomics approaches advance precision oncology and improve clinical outcomes.
Reviewing recent advancements in molecular pathology
Analyzing large-scale consortia data like TCGA and CPTAC
Evaluating clinical outcomes from initiatives like NCI-MATCH trial
Discussing the integration of molecular data with functional outcomes
Multiomics reveals important tumour biology and behaviour
Treatment strategies guided by molecular profiling improve progression-free survival
Genomic analysis alone is insufficient for targeted therapy
Emerging mechanisms of therapeutic resistance are identified through multiomics